CYBIN INC. (HELP) Form 6-K — Aug 10, 2026
Helus Pharma, the commercial operating name of Cybin Inc. (Nasdaq: HELP), announced in a Form 6-K that CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Wednesday, August 12, 2026 at 12:00 p.m. EDT, with a live webcast and replay available on the company's investor relations site. Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists, with lead asset HLP003 in Phase 3 development for the adjunctive treatment of major depressive disorder carrying FDA Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.